Head-to-head evidence
apremilast vs HPP737
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: PDE4 · full Psoriasis pipeline
apremilast · Otezla
Marketed by Amgen
NCT01194219 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 844 participants, with 562 assigned to apremilast and 282 to placebo. The primary clinical endpoint was met: PASI-75 response at Week 16 was 33.1% with apremilast versus 5.3% with placebo (p<0.0001).
Next expected readout: October 2026 · NCT07432386 (registry estimate)
HPP737
Developed by Newsoara Biopharma
NCT07712731 · Phase 3 · completed
The trial randomized 607 participants to HPP737 or active treatment with apremilast and used triple masking of participants, care providers, and investigators. Its primary endpoints were clinical psoriasis measures, but the treatment comparison cannot yet be judged because the registry has not posted results.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: apremilast's landscape · HPP737's landscape